Leap Therapeutics Inc
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Show More...
-
Website https://www.leaptx.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.38 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.04 -2.46 -2.15 -0.71 -1.5 -3.31 -2.11 -1.47 -1.55 Dividends USD Payout Ratio % * Shares Mil 7.0 7.0 12.0 17.0 9.0 9.0 14.0 23.0 26.0 Book Value Per Share * USD 3.28 1.68 1.47 0.94 0.45 0.23 0.5 Free Cash Flow Per Share * USD -1.01 -1.24 -0.57 -2.46 -1.92 -1.38 Return on Assets % -43.8 -95.32 -73.31 -54.92 -148.14 -168.76 -96.14 -250.8 -151.76 Financial Leverage (Average) 1.35 1.1 1.05 1.05 2.61 2.08 1.6 Return on Equity % -59.22 -115.02 -78.34 -57.75 -228.05 -895.74 -237.54 Return on Invested Capital % -60.0 -115.4 -69.67 -57.98 -231.13 -707.93 -223.73 Interest Coverage -4.82 -19.79 -245.98 Current Ratio 10.68 9.93 18.78 21.83 0.11 4.55 2.69 0.5 2.82 Quick Ratio 10.36 9.75 18.71 21.74 0.11 4.52 2.65 0.48 2.8 Debt/Equity 0.03